# Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

> **NCT01566630** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Pre-eclampsia

## Interventions

- **DRUG:** Placebo
- **DRUG:** RLX030

## Key facts

- **NCT ID:** NCT01566630
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Novartis terminated this study due to internal, strategic decisions.
- **Last updated:** 2015-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01566630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01566630, "Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01566630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*